Health
Adjuvant Anti-CDK Thwarts Early Breast Cancer Recurrence – MedPage Today
Risk of invasive recurrence declines 25% in patients with high-risk disease
Including a CDK4/6 inhibitor in adjuvant therapy significantly increased invasive disease-free survival (iDFS) in patients with high-risk early, hormone receptor (HR)-positive breast cancer, a large randomized trial showed.
The hazard for iDFS decreased by 25.3% with the addition of abemaciclib (Verzenio) to standard endocrine therapy. The risk of distant (metastatic) recurrence decreased by almost 30% with combination therapy as compared with endocrine therapy alone.
No new or unexpected toxi…
-
General14 hours agoFour escape injury after jumping from three-storey unit on fire in Newcastle
-
Noosa News13 hours agoGippsland vegetable farm accused of underpaying migrant workers
-
Noosa News14 hours agoThe Best Things to Do in Brisbane This New Year’s Eve
-
Noosa News18 hours agoMary River cod thriving in Brisbane River catchment, century after relative went extinct